The Role of Neopterin as a Monitor of Cellular Immune Activation in Transplantation, Inflammatory, Infectious, and Malignant Diseases

References

• Wachter H, Fuchs D, Hausen A, et al. Neopterin: biochemistry-methods-clinical application. de Gruyter, Berlin-New York 1992
   Google Scholar
• Rembold H, Buschmann L. Struktur und Synthese des Neopterins. Chem Ber 1963; 96: 1406–10
   Google Scholar
• Sakurai A, Goto M. Neopterin: isolation from human urine. J Biochem (Tokyo) 1967; 61: 142–5
   PubMed Web of Science ®Google Scholar
• Danks D M., Cotton R GH, Schlesinger P. Variant forms of phenylketonuria. Lancet 1976; 1: 1236–37
   PubMedGoogle Scholar
• Wachter H, Hausen A, Grapmayr K. Erhöhte Ausscheidung von Neopterin im Harn von Patienten mit malignen Tumoren und mit Viruserkrankungen. Hoppe-Seyler's Z Physiol Chem 1979; 360: 1957–60
   PubMedGoogle Scholar
• Fuchs D, Hausen A, Huber C, et al. Pteridinausscheidung als Marker für alloantigeninduzierte Lymphozytenproliferation. Hoppe-Seyler's Z Physiol Chem 1982; 363: 661–4
   PubMedGoogle Scholar
• Huber C, Fuchs D, Hausen A, et al. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol 1983; 130: 1047–50
   PubMed Web of Science ®Google Scholar
• Huber C, Batchelor J R., Fuchs D, et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon gamma. J Exp Med 1984; 160: 310–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 1988; 9: 150–5
   PubMedGoogle Scholar
• Wachter H, Fuchs D, Hausen A. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem 1989; 27: 81–141
   PubMed Web of Science ®Google Scholar
• Hausen A, Fuchs D, Reibnegger G, et al. Neopterin in clinical use. Pteridines 1989; 1: 3–10
   Google Scholar
• Brown G M. The biosynthesis of pteridines. Adv Enzymol 1971; 35: 5–77
   Google Scholar
• Werner E R., Werner-Felmayer G, Fuchs D, et al. Tetrahydrobiopterin biosynthetic activities in human macrophages, fibroblasts, THP-1, and T24 cells. J Biol Chem 1990; 265: 3189–92
   PubMed Web of Science ®Google Scholar
• Kaufman S. The structure of phenylalanine hydroxylation cofactor. Proc Natl Acad Sci USA 1963; 50: 1085–93
   PubMed Web of Science ®Google Scholar
• Kaufman S. The metabolic role of tetrahydrobiopterin. Chemistry and biology of pteridines, B A. Cooper, V M. Whitehead. Walter de Gruyter, Berlin-New York 1986; 185–200
   Google Scholar
• Tietz A, Lindberg M, Kennedy E P. A new pteridine-requiring enzyme system for the oxidation of glyceryl ethers. J Biol Chem 1964; 239: 4081–90
   PubMed Web of Science ®Google Scholar
• Tayeh M A., Marietta M A. Macrophage oxidation of L-arginine to nitric oxide, nitrite, and nitrate. J Biol Chem 1989; 264: 19654–58
   PubMed Web of Science ®Google Scholar
• Kwon N S., Nathan C F., Stuehr D J. Reduced biopterin as cofactor in the generation of nitrogen oxides by murine macrophages. J Biol Chem 1989; 264: 20496–20501
   PubMed Web of Science ®Google Scholar
• Niederwieser A, Blau N, Wang M, et al. GTP cyciohydrolase I deficiency, a new enzyme defect causing hyperphenylalaninaemia with neopterin, biopterin, dopamine, and serotonin deficiencies and muscular hypotonia. Eur J Paediatr 1984; 141: 208–14
   PubMed Web of Science ®Google Scholar
• Wachter H, Hausen A, Reider E, et al. Pteridine excretion from cells as indicator of cell proliferation. Naturwissenschaften A. 1980; 67: 610–611
   PubMedGoogle Scholar
• Hausen A, Fuchs D, Grünewald K, et al. Urinary neopterin as marker for haematological neoplasias. Clin Chim Acta 1981; 117: 297–305
   PubMed Web of Science ®Google Scholar
• Margreiter R, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation 1983; 36: 650–3
   PubMed Web of Science ®Google Scholar
• Hofmann B, Bass H, Nishanian P, et al. Different lymphoid cell populations produce varied levels of neopterin, ß2-microglobulin and soluble sIL-2 receptor when stimulated witii IL-2, interferon-gamma or tumour necrosis factor-alpha. Clin Exp Immunol 1992; 88: 548–554
   PubMed Web of Science ®Google Scholar
• Werner-Felmayer G, Wemer E R., Fuchs D, et al. Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment. Cancer Res 1990; 50: 2863–67
   PubMed Web of Science ®Google Scholar
• Weiss G, Fuchs D, Hausen A, et al. Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992; 20: 605–10
   PubMed Web of Science ®Google Scholar
• Werner-Felmayer G, Werner E R., Fuchs D, et al. Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med 1990; 172: 1599–1607
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Automatized routine estimation of neopterin in human urine by HPLC on reversed phase. Biochemical and clinical aspects of pteridines, H Wachter, H -C Curtius, W Pfleiderer. Walter de Gruyter, Berlin-New York 1982; 67–79
   Google Scholar
• Duch D S., Bowers S W., Woolf J H., et al. Biopterin cofactor biosynthesis: GTP cyclohydrolase, neopterin and biopterin in tissues and body fluids of mammalian species. Life Sci 1984; 35: 1895–1901
   PubMed Web of Science ®Google Scholar
• Fuchs D, Milstien S, Kramer A, et al. Urinary neopterin concentrations vs total neopterins for clinical utility. Clin Chem 1989; 35: 2305–07
   PubMed Web of Science ®Google Scholar
• Werner E R., Bichler A, Daxenbichler G, et al. Determination of neopterin in serum and urine. Clim Chem 1987; 33: 62–6
   PubMed Web of Science ®Google Scholar
• Hausen A, Fuchs D, König K, et al. Determination of neopterin in human urine by reversed-phase high-performance liquid chromatography. J Chromatogr 1982; 227: 61–70
   PubMed Web of Science ®Google Scholar
• Werner E R., Fuchs D, Hausen A, et al. Simultaneous determination of neopterin and creatinine in serum with solid phase extraction and on-line elution liquid chromatography. Clin Chem 1987; 33: 2028–33
   PubMed Web of Science ®Google Scholar
• Weiss G, Glaser K, Kronberger P, et al. Distinct distribution of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation. Biol Chem Hoppe Seyler 1992; 373: 289–94
   PubMed Web of Science ®Google Scholar
• Nathan C F. Peroxide and pteridine: a hypothesis of the regulation of macrophage antimicrobial activity by interferon gamma. Interferon, J Gresser. Academic Press, London 1986; 7: 125–143
   Google Scholar
• Barak M, Gruener N. Neopterin augmentation of tumor necrosis factor production. Immunol Lett 1991; 30: 101–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1990; 46: 65–70
   Web of Science ®Google Scholar
• Wachter H, Artner-Dworzak E, Fuchs D, et al. Association between neopterin and iron metabolism in cancer patients. Tumor Diagn Ther 1991; 11: 229–32
   Google Scholar
• Denz H, Huber P, Landmann R, et al. Association between the activation of macrophages, changes of iron metabolism and the degree of anaemia in patients with malignant disorders. Eur J Haematol 1992; 48: 245–9
   Web of Science ®Google Scholar
• Reibnegger G, Aichberger C, Fuchs D, et al. Posttransplant neopterin excretion in renal allograft recipients: reliable diagnostic aid of acute rejection and predictive marker of longterm graft survival. Transplantation 1991; 52: 58–63
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Neopterin levels in long-term hemodialysis. Clin Nephrol 1988; 30: 220–4
   PubMed Web of Science ®Google Scholar
• Aulitzky W E., Tilg H, Niederwieser D, et al. Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients. Clin Nephrol 1988; 29: 248–52
   PubMed Web of Science ®Google Scholar
• Tilg H, Margreiter R, Scriba M, et al. Clinical presentation of CMV infection in solid organ transplant recipients and its impact on graft rejection and neopterin excretion. Clin Transplantation 1987; 1: 37–43
   Google Scholar
• Tilg H, Vogel W, Aulitzky W E., et al. Neopterin excretion after liver transplantation and its value in differential diagnosis of complications. Transplantation 1989; 48: 594–9
   PubMed Web of Science ®Google Scholar
• Havel M, Laczkovics A, Teufelsbauer H, et al. Neopterin as a new marker to detect acute rejection after heart transplantation. J Heart Transplant 1989; 8: 167–70
   PubMedGoogle Scholar
• Brattström C, Tyden G, Reinholt F P., et al. Markers for pancreas-graft rejection in humans. Diabetes 1989; 38(Suppl. 1)57–62
   PubMedGoogle Scholar
• Königsrainer A, Reibnegger G, Ofner D, et al. Pancreatic juice neopterin excretion: reliable marker for detection of pancreatic allograft rejection. Transplant Proc 1990; 22: 671–2
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Huber C, Gratwohl A, et al. Neopterin as a new biochemical marker in the clinical monitoring of bone marrow transplant recipients. Transplantation 1984; 38: 497–500
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Egg D, Fuchs D, et al. Urinary neopterin reflects clinical activity in patients with rheumatoid arthritis. Arthritis Rheum 1986; 29: 1063–70
   PubMed Web of Science ®Google Scholar
• Krause A, Protz H, Goebel K M. Correlation between synovial neopterin and inflammatory activity in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 636–40
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Bollbach R, Fuchs D, et al. A simple index relating clinical activity in Crohn's disease with T cell activation: hematocrit, frequency of liquid stools and urinary neopterin as parameters. Immunobiology 1986; 173: 1–11
   PubMed Web of Science ®Google Scholar
• Granditsch G, Fuchs D, Hausen A, et al. Urinary neopterin as marker for disease activity in children and adolescents with Crohn's disease. Pteridines 1990; 2: 23–7
   Google Scholar
• Niederwieser D, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology 1985; 170: 320–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Granditsch G, Hausen A, et al. Urinary neopterin excretion in coeliac disease. Lancet 1983; 2: 463–4
   PubMed Web of Science ®Google Scholar
• Manna R, Gambassi G, Papa G, et al. Urinary neopterin levels of insulin dependent diabetes (IDDM) at onset. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, H C. Curtius. Walter de Gruyter, Berlin-New York 1987; 353–7
   Google Scholar
• Schwedes U, Teuber J, Schmidt R, et al. Neopterin as a marker for the activity of autoimmune thyroid diseases. Acta Endocrinol 1986; 111: 51–2
   Google Scholar
• Leohirun L, Thuvasethakul P, Sumethkul V, et al. Urinary neopterin in patients with systemic lupus erythematosus. Clin Chem 1991; 37: 47–50
   PubMed Web of Science ®Google Scholar
• Fredrikson S, Link H, Eneroth P. CSF neopterin as marker of disease activity in multiple sclerosis. Acta Neurol Scand 1987; 75: 352–5
   PubMed Web of Science ®Google Scholar
• Eklund A, Blaschke E. Elevated serum neopterin levels in sarcoidosis. Lung 1986; 164: 325–32
   PubMed Web of Science ®Google Scholar
• Prior C, Frank A, Fuchs D, et al. Urinary neopterin excretion value in pulmonary sarcoidosis: correlation to clinical course of the disease. Clin Chim Acta 1988; 177: 211–20
   PubMed Web of Science ®Google Scholar
• Lacronique J, Auzeby A, Valeyre D, et al. Urinary neopterin in pulmonary sarcoidosis. Relationship to clinical and biologic assessment of the disease. Am Rev Respir Dis 1989; 139: 1474–8
   PubMedGoogle Scholar
• Rudzite V, Skards J I., Fuchs D, et al. Serum kynurenine and neopterin concentrations in patients with cardiomyopathy. Immunol Lett 1992; 32: 125–30
   PubMed Web of Science ®Google Scholar
• Samsonov M, Fuchs D, Reibnegger G, et al. Patterns of serological markers for cellular immune activation in patients with dilated cardiomyopathy and chronic myocarditis. Clin Chem 1992; 38: 678–80
   PubMed Web of Science ®Google Scholar
• Samsonov M, Nassonov E, Dhzuzenova B, et al. Serum neopterin in acute rheumatic fever. Clin Chem
   Web of Science ®Google Scholar
• Tatzber F, Rabl H, Koriska K, et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis 1991; 89: 203–8
   PubMed Web of Science ®Google Scholar
• Hausen A, Fuchs D, Griinewald K, et al. Urinary neopterin in the assessment of lymphoid and myeloid neoplasia, and neopterin levels in haemolytic anaemia and benign monoclonal gammopathy. Clin Biochem 1982; 15: 34–7
   PubMed Web of Science ®Google Scholar
• Abate G, Cornelia P, Marfella A, et al. Prognostic relevance of urinary neopterin in non-Hodgkin's lymphomas. Cancer 1989; 63: 484–9
   PubMed Web of Science ®Google Scholar
• Thomas P, Mura P, Tallineau C, et al. Intérět du dosage de la néoptérine urinaire dans le myélome multiple. Rev Rhum 1985; 52: 381–3
   PubMedGoogle Scholar
• Reibnegger G, Fuchs D, Hausen A, et al. Urinary neopterin in malignant diseases of childhood. A marker for activity of the cell-mediated immunity. Tumor Diagn Ther 1984; 5: 234–7
   Google Scholar
• Denz H, Grünewald K, Thaler J, et al. Urinary neopterin as a prognostic marker in hae-matological neoplasias. Pteridines 1989; 1: 167–70
   Google Scholar
• Reibnegger G, Hetzel H, Fuchs D, et al. Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987; 47: 4977–81
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Bichler A, Dapunt O, et al. Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix. Cancer Res 1986; 46: 950–5
   PubMed Web of Science ®Google Scholar
• Fuith L C., Fuchs D, Hausen A, et al. Urinary neopterin excretion value in patients with uterine sarcomas. Cancer 1990; 65: 1228–31
   PubMed Web of Science ®Google Scholar
• Aulitzky W, Frick J, Fuchs D, et al. Significance of urinary neopterin in patients with malignant tumors of the genitourinary tract. Cancer 1985; 55: 1052–5
   PubMed Web of Science ®Google Scholar
• Lewenhaupt A, Ekman P, Eneroth P, et al. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986; 12: 422–5
   PubMed Web of Science ®Google Scholar
• Joos H, Aulitzky W, Frick J, et al. Die Urin-Neopterin-Ausscheidung beim Hodentumorpatienten-ein biochemischer Parameter. Helv Chim Acta 1986; 53: 329–31
   Google Scholar
• Conrad F, Fuchs D, Hausen A, et al. Prognostic value of neopterin in patients with lung cancer. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, J A. Blair. Walter de Gruyter, Berlin-New York 1987; 233–241
   Google Scholar
• von Ingersleben G, Souchon R, Fitzner R. Serum neopterin levels in lung and breast cancer patients undergoing radiotherapy and/or chemotherapy. Int J Biol Markers 1988; 3: 135–9
   PubMedGoogle Scholar
• Conrad F, Bodner E, Fuchs D, et al. Determination of neopterin-a marker of cellular immunity-in gastrointestinal and pancreatic carcinoma. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, H -C Curtius. Walter de Gruyter, Berlin-New York 1984; 357–66
   Google Scholar
• Putzki H, Aschern F, Henkel E, et al. Neopterin-a tumor marker in colorectal carcinoma. Dis Colon Rectum 1987; 30: 879–83
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Watanabe H, Yamada S, et al. Prognostic significance of urinary neopterin levels in patients with hepatocellular carcinoma. Tohoku J Exp Med 1988; 155: 311–8
   PubMed Web of Science ®Google Scholar
• Wiegele J, Margreiter R, Huber C, et al. Urinary neopterin excretion value in breast cancer patients. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, H -C Curtius. Walter de Gruyter, Berlin-New York 1984; 417–24
   Google Scholar
• Reibnegger G, Fuchs D, Hausen A, et al. Urinary neopterin in patients with head and neck cancer. Biochemical and clinical aspects of pteridines, H Wachter, H -C Curtius, W Pfleiderer. Walter de Gruyter, Berlin-New York 1982; 207–15
   Google Scholar
• Fuith L C., Dapunt O, Hetzel H, et al. Second-look operation in women with ovarian cancer; I. Concentrations of neopterin in urine and CA 125 in serum at second-look laparotomy their relationship with prognosis. Tumor Diagn Ther 1990; 11: 147–51
   Google Scholar
• Mura P, Barriere M, Papet Y, et al. The clinical significance of urinary neopterin in the follow-up of patients after exeresis of a malignant melanoma. Pteridines 1989; 1: 19–21
   Google Scholar
• Schuster V, Reibnegger G, Wachter H. Neopterin and endogenous interferon gamma in serum of patients with Epstein-Barr virus-associated lymphoproliferative diseases. Pteridines 1990; 2: 189–91
   Google Scholar
• Reibnegger G, Fuchs D, Grubauer G, et al. Neopterin excretion during incubation period, clinical manifestation and reconvalescence of viral infection. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, H -C Curtius. Walter de Gruyter, Berlin-New York 1984; 433–47
   Google Scholar
• Griffin D E., Ward B J., Jauregui E, et al. Immune activation during measles, interferon gamma and neopterin in plasma and cerebrospinal fluid in complicated and uncomplicated disease. J Infect Dis 1990; 161: 449–53
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Auhuber I, Fuchs D, et al. Urinary neopterin levels in acute viral hepatitis. Hepatology 1988; 8: 771–4
   PubMed Web of Science ®Google Scholar
• Prior C, Fuchs D, Hausen A, et al. Potential of urinary neopterin excretion in differentiating chronic non-A, non-B hepatitis from fatty liver. Lancet 1987; 2: 1235–7
   PubMed Web of Science ®Google Scholar
• Reibnegger G, Fuchs D, Hausen A, et al. The dependence of cell-mediated immune activation in malaria on age and endemicity. Trans R Soc Trop Med Hyg 1987; 81: 729–33
   PubMed Web of Science ®Google Scholar
• Kern P, Hemmer C J., Van Damme J, et al. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989; 87: 139–43
   PubMed Web of Science ®Google Scholar
• Brown A E., Webster H K., Teja-Isavadharm P, et al. Macrophage activation in falciparum malaria as measured by neopterin and interferon gamma. Clin Exp Immunol 1990; 82: 97–101
   PubMed Web of Science ®Google Scholar
• Zwingenberger K, Feldmeier H, Queiroz Nogueira JA, et al. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers. Parasitol Res 1988; 74: 448–55
   PubMed Web of Science ®Google Scholar
• Fuchs D, Hausen A, Kofler M, et al. Neopterin as an index of immune response in patients with tuberculosis. Lung 1984; 162: 337–46
   PubMed Web of Science ®Google Scholar
• Schmutzhard E, Fuchs D, Hausen A, et al. Is neopterin-a marker of cell-mediated immune response-helpful in classifying leprosy. East Afr Med J 1986; 63: 577–80
   PubMed Web of Science ®Google Scholar
• Brown A E., Dance D AB, Chaowagul W, et al. Activation of cellular immune responses in melioidosis patients as assessed by urinary neopterin. Trans R Soc Trop Med Hyg 1990; 84: 583–4
   PubMed Web of Science ®Google Scholar
• Dotevall L, Fuchs D, Reibnegger G, et al. Cerebrospinal fluid and serum neopterin levels in patients with Lyme neuroborreliosis. Infection 1990; 18: 210–4
   PubMed Web of Science ®Google Scholar
• Denz H, Fuchs D, Hausen A, et al. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klin Wochenschr 1990; 68: 218–22
   PubMedGoogle Scholar
• Strohmaier W, Redl H, Schlag G, et al. D-Erythro-neopterin plasma levels in intensive care patients with and without septic complications. Crit Care Med 1987; 15: 757–60
   PubMed Web of Science ®Google Scholar
• Robin B, Fuchs D, Koller W, et al. Course of immune activation markers in patients after severe multiple trauma. Pteridines 1990; 2: 95–7
   Google Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Distinct neopterin excretion patterns after vaccination. Pteridines 1990; 2: 147–9
   Google Scholar
• Wachter H, Fuchs D, Hausen A, et al. Elevated urinary neopterin levels in patients with the acquired immunodeficiency syndrome. Hoppe-Seyler's Z Physiol Chem 1983; 364: 1345–6
   PubMedGoogle Scholar
• Fuchs D, Hausen A, Reibnegger G, et al. Urinary neopterin the diagnosis of acquired immune deficiency syndrome. Eur J Clin Microbiol 1984; 3: 70–1
   PubMedGoogle Scholar
• Fuchs D, Reibnegger G, Wachter H, et al. Neopterin levels correlating with the Walter Reed Staging classification in human immunodeficiency virus (HIV) infection. Ann Intern Med 1987; 107: 784–5
   PubMed Web of Science ®Google Scholar
• Fuchs D, Chiodi F, Albert J, et al. Neopterin concentrations in cerebrospinal fluid and serum of individuals infected with HIV-1. AIDS 1989; 3: 285–8
   PubMed Web of Science ®Google Scholar
• Melmed R N., Taylor J MG, Detels R, et al. Serum neopterin changes in HIV infected subjects: indicator of significant pathology, CD4 T cell changes, and the development of AIDS. J Acquir Immune Defic Syndr 1989; 2: 70–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Albert J, Asjö B, et al. Association between serum neopterin concentrations and in vitro replicative capacity of HIV-1 isolates. J Infect Dis 1989; 160: 724–5
   PubMed Web of Science ®Google Scholar
• Fuchs D, Banekovich M, Hausen A, et al. Neopterin estimation compared with the ratio of T cell subpopulations in persons infected with human immunodeficiency virus-1. Clin Chem 1988; 34: 2415–7
   PubMed Web of Science ®Google Scholar
• Fuchs D, Shearer G M., Boswe U RN, et al. Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol 1990; 80: 44–8
   PubMed Web of Science ®Google Scholar
• Fuchs D, Malkovsky M, Reibnegger G, et al. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 1989; 23: 103–8
   PubMed Web of Science ®Google Scholar
• Sönnerborg A, Ehmst A, Bérgdahl S, et al. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988; 2: 89–93
   PubMed Web of Science ®Google Scholar
• Zangerle R, Schönitzer D, Fuchs D, et al. Reducing HIV transmission by seronegative blood. Lancet 1992; 339: 130–1
   PubMed Web of Science ®Google Scholar
• Fendrich C, Lüke W, Stahl-Hennig C, et al. Urinary neopterin concentrations in rhesus monkeys after infection with simian immunodeficiency virus (SIV mac251). AIDS 1989; 3: 305–7
   PubMed Web of Science ®Google Scholar
• Stahl-Hennig C, Voss G, Nick S, et al. Immunization with tween-ether-treated SIV adsorbed onto aluminium hydroxide protects monkeys against experimental SIV infection. Virology 1992; 186: 588–96
   PubMed Web of Science ®Google Scholar
• Popov J, McGraw T, Hofmann B, et al. Acute lymphoid changes and ongoing immune activation in SIV infection. J Acquir Immune Defic Syndr 1992; 5: 391–9
   PubMed Web of Science ®Google Scholar
• Krämer A, Wiktor S Z., Fuchs D, et al. Neopterin: a predictive marker of acquired immune deficiency syndrome in human immunodeficiency virus infection. J Acquir Immune Defic Syndr 1989; 2: 291–6
   PubMed Web of Science ®Google Scholar
• Fuchs D, Spira T J., Hausen A, et al. Neopterin as a predictive marker for disease progression in human immunodeficiency virus type 1 infection. Clin Chem 1989; 35: 1746–9
   PubMed Web of Science ®Google Scholar
• Fahey J L., Taylor J MG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322: 166–72
   PubMed Web of Science ®Google Scholar
• Fuchs D, Jäger H, Popescu M, et al. Immune activation markers to predict AIDS and survival in HIV-1 seropositives. Immunol Lett 1990; 26: 75–80
   PubMed Web of Science ®Google Scholar
• Zangerle R, Fuchs D, Reibnegger G, et al. Markers for disease progression in intravenous drug users infected with HIV-1. AIDS 1991; 5: 985–91
   PubMed Web of Science ®Google Scholar
• Fuchs D, Krämer A, Reibnegger G, et al. Neopterin and ß2-microglobulin as prognostic indices in human immunodeficiency virus type 1 infection. Infection 1991; 19(Suppl 2)98–102
   PubMedGoogle Scholar
• Ellaurie M, Calvelli T, Rubinstein A. Neopterin concentrations in pediatric human immunodeficiency virus infection as predictor of disease activity. Pediatr Infect Dis 1992; 11: 286–9
   Google Scholar
• Krämer A, Biggar R J., Frieman R M., et al. Immunologic AIDS progression markers are time-dependent and illness specific. Am J Epidemiol 1992; 136: 71–80
   PubMed Web of Science ®Google Scholar
• Jacobson M A., Bacchetti P, Kolokathis A, et al. Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. Br Med J 1991; 302: 73–8
   PubMed Web of Science ®Google Scholar
• Hutterer J, Armbruster C, Wallner G, et al. Early changes of neopterin concentrations during treatment of human immunodeficiency virus infection with zidovudine. J Infect Dis 1992; 165: 783–4
   PubMed Web of Science ®Google Scholar
• Bass H Z., Hardy W D., Mitsuyasu R T., et al. The effect of zidovudine treatment on serum neopterin and beta2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Acquir Immune Defic Syndr 1992; 5: 215–21
   PubMed Web of Science ®Google Scholar
• Sönnerborg A B., von Stedingk L -V, Hansson L -O, et al. Elevated neopterin and beta-2 microglobulin levels in blood and cerebrospinal fluid occur early in HIV-1 infection. AIDS 1989; 3: 277–83
   PubMed Web of Science ®Google Scholar
• Brew B J., Bhalla R B., Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990; 28: 556–60
   PubMed Web of Science ®Google Scholar
• Griffin D E., McArthur J C., Cornblath D R. Neopterin and interferon gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41: 69–74
   PubMed Web of Science ®Google Scholar
• Fuchs D, Möller A A., Reibnegger G, et al. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990; 3: 873–6
   PubMed Web of Science ®Google Scholar
• Lang A, Niederwieser D, Huber C, et al. Treatment with human recombinant interferon alpha-2 induces increase of in vivo neopterin excretion. Biochemical and clinical aspects of pteridines, W Pfleiderer, H Wachter, H C. Curtius. Walter de Gruyter, Berlin-New York 1984; 251–254
   Google Scholar
• Schiller J H., Storer B, Paulnock D M., et al. A direct comparison of biological response modulation and clinical side effects by interferon beta-ser, interferon gamma, or the combination of interferons beta-ser and gamma in humans. J Clin Invest 1990; 86: 1211–21
   PubMed Web of Science ®Google Scholar
• Brown R R., Lee C M., Kohler P C., et al. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res 1989; 49: 4941–4
   PubMed Web of Science ®Google Scholar
• Aulitzky W E., Tilg H, Herold M, et al. Enhanced serum levels of beta-2 microglobulin, neopterin, and interferon gamma in patients treated with recombinant tumor necrosis factor alpha. J Interferon Res 1988; 8: 655–64
   PubMedGoogle Scholar
• Goldstein D, Sielaff K M., Storer B E., et al. Human biological response modification in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon beta-serine. J Natl Cancer Inst 1989; 81: 1061–8
   PubMed Web of Science ®Google Scholar
• Gastl G, Werter M, De Pauw B, et al. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients. Leukemia 1989; 3: 453–60
   PubMed Web of Science ®Google Scholar
• Fuchs D, Norkrans G, Wejstal R, et al. Neopterin, beta-2 microglobulin and interferon gamma levels in patients with non-A/non-B hepatitis before and during treatment with interferon alpha-2b. Eur J Med 1992; 1: 196–200
   PubMedGoogle Scholar
• Spemer-Unterweger B, Barnas C, Fleischhacker W W., et al. Is schizophrenia linked to alteration in cellular immunity. Schizophrenia Res 1989; 2: 417–21
   PubMed Web of Science ®Google Scholar
• Spemer-Unterweger B, Bamas C, Fuchs D, et al. Neopterin als Parameter der T-Zell-und Makrophagenaktivierung bei psychiatrischen Erkrankungen. Biologische psychiatrie, B Salem. Thieme Verlag, Stuttgart-New York 1989; 108–112
   Google Scholar
• Cowburn J D., Farrar G, Blair J A. Alzheimer's disease-some biochemical clues. Chem Brit 1990; 26: 1169–73
   Google Scholar
• Hönlinger M, Fuchs D, Hausen A, et al. Serum-Neopterinbestimmung zur zusätzlichen Sicherung der Bluttransfusion. Erfahrungen an 76587 Blutspendern. Dtsch Med Wochenschr 1989; 114: 172–6
   PubMed Web of Science ®Google Scholar
• Hönlinger M, Fuchs D, Reibnegger G, et al. Neopterin screening and acute cytomegalovirus infections in blood donors. Clin Invest 1992; 70: 63
   PubMedGoogle Scholar
• Peters K M., Leusch H -G, Bruchhausen B, et al. Neopterinbestimmung zum Screening von Spongiosaspendem. Z Orthop 1990; 128: 453–6
   PubMedGoogle Scholar